{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:43:34Z","timestamp":1794408214708,"version":"4.9.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"8064","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2025,5,22]]},"DOI":"10.1038\/s41586-025-08700-0","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T11:03:26Z","timestamp":1744801406000},"page":"971-977","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":234,"title":["Phase I\/II trial of iPS-cell-derived dopaminergic cells for Parkinson\u2019s disease"],"prefix":"10.1038","volume":"641","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8695-0223","authenticated-orcid":false,"given":"Nobukatsu","family":"Sawamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0992-1220","authenticated-orcid":false,"given":"Daisuke","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuro","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Sawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hodaka","family":"Yamakado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Taruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Shima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1982-3168","authenticated-orcid":false,"given":"Yasutaka","family":"Fushimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2312-5677","authenticated-orcid":false,"given":"Tomohisa","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2332-4967","authenticated-orcid":false,"given":"Tetsuhiro","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7411-1828","authenticated-orcid":false,"given":"Asuka","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoe","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7625-5750","authenticated-orcid":false,"given":"Takayuki","family":"Anazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2085-6151","authenticated-orcid":false,"given":"Takero","family":"Shindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4626-4645","authenticated-orcid":false,"given":"Yoshiki","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1407-9640","authenticated-orcid":false,"given":"Ryosuke","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3642-9186","authenticated-orcid":false,"given":"Jun","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"8700_CR1","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1056\/NEJM199504273321702","volume":"332","author":"JH Kordower","year":"1995","unstructured":"Kordower, J. H. et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson\u2019s disease. N. Engl. J. Med. 332, 1118\u20131124 (1995).","journal-title":"N. Engl. J. Med."},{"key":"8700_CR2","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/16060","volume":"2","author":"P Piccini","year":"1999","unstructured":"Piccini, P. et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson\u2019s patient. Nat. Neurosci. 2, 1137\u20131140 (1999).","journal-title":"Nat. Neurosci."},{"key":"8700_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/S1474-4422(12)70295-8","volume":"12","author":"RA Barker","year":"2013","unstructured":"Barker, R. A., Barrett, J., Mason, S. L. & Bjorklund, A. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson\u2019s disease. Lancet Neurol. 12, 84\u201391 (2013).","journal-title":"Lancet Neurol."},{"key":"8700_CR4","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJM200103083441002","volume":"344","author":"CR Freed","year":"2001","unstructured":"Freed, C. R. et al. Transplantation of embryonic dopamine neurons for severe Parkinson\u2019s disease. N. Engl. J. Med. 344, 710\u2013719 (2001).","journal-title":"N. Engl. J. Med."},{"key":"8700_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.10720","volume":"54","author":"CW Olanow","year":"2003","unstructured":"Olanow, C. W. et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson\u2019s disease. Ann. Neurol. 54, 403\u2013414 (2003).","journal-title":"Ann. Neurol."},{"key":"8700_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41583-019-0257-7","volume":"21","author":"M Parmar","year":"2020","unstructured":"Parmar, M., Grealish, S. & Henchcliffe, C. The future of stem cell therapies for Parkinson disease. Nat. Rev. Neurosci. 21, 103\u2013115 (2020).","journal-title":"Nat. Rev. Neurosci."},{"key":"8700_CR7","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/s41591-019-0507-2","volume":"25","author":"RA Barker","year":"2019","unstructured":"Barker, R. A. & TRANSEURO Consortium. Designing stem-cell-based dopamine cell replacement trials for Parkinson\u2019s disease. Nat. Med. 25, 1045\u20131053 (2019).","journal-title":"Nat. Med."},{"key":"8700_CR8","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1915872","volume":"382","author":"JS Schweitzer","year":"2020","unstructured":"Schweitzer, J. S. et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson\u2019s disease. N. Engl. J. Med. 382, 1926\u20131932 (2020).","journal-title":"N. Engl. J. Med."},{"key":"8700_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.stem.2021.01.004","volume":"28","author":"J Piao","year":"2021","unstructured":"Piao, J. et al. Preclinical efficacy and safety of a human embryonic stem cell-derived midbrain dopamine progenitor product, MSK-DA01. Cell Stem Cell 28, 217\u2013229 (2021).","journal-title":"Cell Stem Cell"},{"key":"8700_CR10","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.stem.2023.08.014","volume":"30","author":"A Kirkeby","year":"2023","unstructured":"Kirkeby, A. et al. Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson\u2019s disease, STEM-PD. Cell Stem Cell 30, 1299\u20131314 (2023).","journal-title":"Cell Stem Cell"},{"key":"8700_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.stemcr.2014.01.013","volume":"2","author":"D Doi","year":"2014","unstructured":"Doi, D. et al. Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. Stem Cell Rep. 2, 337\u2013350 (2014).","journal-title":"Stem Cell Rep."},{"key":"8700_CR12","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nature23664","volume":"548","author":"T Kikuchi","year":"2017","unstructured":"Kikuchi, T. et al. Human iPS cell-derived dopaminergic neurons function in a primate Parkinson\u2019s disease model. Nature 548, 592\u2013596 (2017).","journal-title":"Nature"},{"key":"8700_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17165-w","volume":"11","author":"D Doi","year":"2020","unstructured":"Doi, D. et al. Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson\u2019s disease. Nat. Commun. 11, 3369 (2020).","journal-title":"Nat. Commun."},{"key":"8700_CR14","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"8700_CR15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nmeth.1591","volume":"8","author":"K Okita","year":"2011","unstructured":"Okita, K. et al. A more efficient method to generate integration-free human iPS cells. Nat. Methods 8, 409\u2013412 (2011).","journal-title":"Nat. Methods"},{"key":"8700_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.medj.2022.10.003","volume":"4","author":"S Yoshida","year":"2023","unstructured":"Yoshida, S. et al. A clinical-grade HLA haplobank of human induced pluripotent stem cells matching approximately 40% of the Japanese population. Med 4, 51\u201366 (2023).","journal-title":"Med"},{"key":"8700_CR17","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s00259-016-3444-z","volume":"43","author":"C Feeney","year":"2016","unstructured":"Feeney, C. et al. Kinetic analysis of the translocator protein positron emission tomography ligand [(18)F]GE-180 in the human brain. Eur. J. Nucl. Med. Mol. Imaging 43, 2201\u20132210 (2016).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"8700_CR18","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1002\/mds.22341","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz, C. G., Nutt, J. G. & Stebbins, G. T. The unified dyskinesia rating scale: presentation and clinimetric profile. Mov. Disord. 23, 2398\u20132403 (2008).","journal-title":"Mov. Disord."},{"key":"8700_CR19","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz, C. G. et al. Movement Disorder Society\u2014sponsored revision of the Unified Parkinson\u2019s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23, 2129\u20132170 (2008).","journal-title":"Mov. Disord."},{"key":"8700_CR20","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson, C. L. et al. Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov. Disord. 25, 2649\u20132653 (2010).","journal-title":"Mov. Disord."},{"key":"8700_CR21","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/mds.29410","volume":"38","author":"ST Jost","year":"2023","unstructured":"Jost, S. T. et al. Levodopa dose equivalency in Parkinson\u2019s disease: updated systematic review and proposals. Mov. Disord. 38, 1236\u20131252 (2023).","journal-title":"Mov. Disord."},{"key":"8700_CR22","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/archneur.1989.00520420033021","volume":"46","author":"O Lindvall","year":"1989","unstructured":"Lindvall, O. et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson\u2019s disease. A detailed account of methodology and a 6-month follow-up. Arch. Neurol. 46, 615\u2013631 (1989).","journal-title":"Arch. Neurol."},{"key":"8700_CR23","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1126\/science.2105529","volume":"247","author":"O Lindvall","year":"1990","unstructured":"Lindvall, O. et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson\u2019s disease. Science 247, 574\u2013577 (1990).","journal-title":"Science"},{"key":"8700_CR24","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nn863","volume":"5","author":"P Hagell","year":"2002","unstructured":"Hagell, P. et al. Dyskinesias following neural transplantation in Parkinson\u2019s disease. Nat. Neurosci. 5, 627\u2013628 (2002).","journal-title":"Nat. Neurosci."},{"key":"8700_CR25","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.expneurol.2005.10.022","volume":"197","author":"KS Bankiewicz","year":"2006","unstructured":"Bankiewicz, K. S. et al. Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys. Exp. Neurol. 197, 363\u2013372 (2006).","journal-title":"Exp. Neurol."},{"key":"8700_CR26","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.stem.2010.07.003","volume":"7","author":"RA Barker","year":"2010","unstructured":"Barker, R. A. & Kuan, W. L. Graft-induced dyskinesias in Parkinson\u2019s disease: what is it all about? Cell Stem Cell 7, 148\u2013149 (2010).","journal-title":"Cell Stem Cell"},{"key":"8700_CR27","doi-asserted-by":"publisher","first-page":"38ra46","DOI":"10.1126\/scitranslmed.3000976","volume":"2","author":"M Politis","year":"2010","unstructured":"Politis, M. et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson\u2019s patients with neural transplants. Sci. Transl. Med. 2, 38ra46 (2010).","journal-title":"Sci. Transl. Med."},{"key":"8700_CR28","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1002\/mds.23743","volume":"26","author":"M Politis","year":"2011","unstructured":"Politis, M. et al. Graft-induced dyskinesias in Parkinson\u2019s disease: High striatal serotonin\/dopamine transporter ratio. Mov. Disord. 26, 1997\u20132003 (2011).","journal-title":"Mov. Disord."},{"key":"8700_CR29","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3171\/jns.2002.96.3.0589","volume":"96","author":"I Mendez","year":"2002","unstructured":"Mendez, I. et al. Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study. Report of three cases. J. Neurosurg. 96, 589\u2013596 (2002).","journal-title":"J. Neurosurg."},{"key":"8700_CR30","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.stemcr.2013.08.007","volume":"1","author":"A Morizane","year":"2013","unstructured":"Morizane, A. et al. Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate. Stem Cell Rep. 1, 283\u2013292 (2013).","journal-title":"Stem Cell Rep."},{"key":"8700_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00926-5","volume":"8","author":"A Morizane","year":"2017","unstructured":"Morizane, A. et al. MHC matching improves engraftment of iPSC-derived neurons in non-human primates. Nat. Commun. 8, 385 (2017).","journal-title":"Nat. Commun."},{"key":"8700_CR32","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nm1746","volume":"14","author":"JY Li","year":"2008","unstructured":"Li, J. Y. et al. Lewy bodies in grafted neurons in subjects with Parkinson\u2019s disease suggest host-to-graft disease propagation. Nat. Med. 14, 501\u2013503 (2008).","journal-title":"Nat. Med."},{"key":"8700_CR33","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/brain\/awh510","volume":"128","author":"I Mendez","year":"2005","unstructured":"Mendez, I. et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson\u2019s disease. Brain 128, 1498\u20131510 (2005).","journal-title":"Brain"},{"key":"8700_CR34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3233\/JPD-212610","volume":"12","author":"S Polgar","year":"2022","unstructured":"Polgar, S. et al. The placebo response in double-blind randomised trials evaluating regenerative therapies for Parkinson\u2019s disease: a systematic review and meta-analysis. J. Parkinsons Dis. 12, 759\u2013771 (2022).","journal-title":"J. Parkinsons Dis."},{"key":"8700_CR35","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1126\/science.1060937","volume":"293","author":"R de la Fuente-Fernandez","year":"2001","unstructured":"de la Fuente-Fernandez, R. et al. Expectation and dopamine release: mechanism of the placebo effect in Parkinson\u2019s disease. Science 293, 1164\u20131166 (2001).","journal-title":"Science"},{"key":"8700_CR36","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1172\/JCI68295","volume":"123","author":"I Aviles-Olmos","year":"2013","unstructured":"Aviles-Olmos, I. et al. Exenatide and the treatment of patients with Parkinson\u2019s disease. J. Clin. Invest. 123, 2730\u20132736 (2013).","journal-title":"J. Clin. Invest."},{"key":"8700_CR37","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/mds.21429","volume":"22","author":"A Schrag","year":"2007","unstructured":"Schrag, A. et al. Rate of clinical progression in Parkinson\u2019s disease. A prospective study. Mov. Disord. 22, 938\u2013945 (2007).","journal-title":"Mov. Disord."},{"key":"8700_CR38","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/1531-8249(200011)48:5<689::AID-ANA1>3.0.CO;2-N","volume":"48","author":"P Piccini","year":"2000","unstructured":"Piccini, P. et al. Delayed recovery of movement-related cortical function in Parkinson\u2019s disease after striatal dopaminergic grafts. Ann. Neurol. 48, 689\u2013695 (2000).","journal-title":"Ann. Neurol."},{"key":"8700_CR39","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.neuroimage.2011.03.012","volume":"56","author":"N Pavese","year":"2011","unstructured":"Pavese, N., Rivero-Bosch, M., Lewis, S. J., Whone, A. L. & Brooks, D. J. Progression of monoaminergic dysfunction in Parkinson\u2019s disease: a longitudinal 18F-dopa PET study. Neuroimage 56, 1463\u20131468 (2011).","journal-title":"Neuroimage"},{"key":"8700_CR40","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1093\/brain\/awf237","volume":"125","author":"NL Khan","year":"2002","unstructured":"Khan, N. L. et al. Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain 125, 2248\u20132256 (2002).","journal-title":"Brain"},{"key":"8700_CR41","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/mds.1139","volume":"16","author":"E Nurmi","year":"2001","unstructured":"Nurmi, E. et al. Rate of progression in Parkinson\u2019s disease: a 6-[18F]fluoro-l-dopa PET study. Mov. Disord. 16, 608\u2013615 (2001).","journal-title":"Mov. Disord."},{"key":"8700_CR42","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1001\/jamaneurol.2013.4749","volume":"71","author":"Z Kefalopoulou","year":"2014","unstructured":"Kefalopoulou, Z. et al. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol. 71, 83\u201387 (2014).","journal-title":"JAMA Neurol."},{"key":"8700_CR43","unstructured":"Fahn, S., Elton, R. L. & UPDRS Development Committee. in Recent Developments in Parkinson\u2019s Disease Vol. 2 (eds Fahn, S. et al.) 153\u2013163 (Macmillan, 1987)."},{"key":"8700_CR44","doi-asserted-by":"crossref","unstructured":"Takahashi, J. Next steps in regenerative medicine. Cell Stem Cell 30, 509\u2013511 (2023).","DOI":"10.1016\/j.stem.2023.04.015"},{"key":"8700_CR45","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/jcbfm.1985.87","volume":"5","author":"CS Patlak","year":"1985","unstructured":"Patlak, C. S. & Blasberg, R. G. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb. Blood Flow Metab. 5, 584\u2013590 (1985).","journal-title":"J Cereb. Blood Flow Metab."},{"key":"8700_CR46","doi-asserted-by":"crossref","unstructured":"Shields, A. F. et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat. Med. 4, 1334\u20131336 (1998).","DOI":"10.1038\/3337"},{"key":"8700_CR47","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/ar.1090940210","volume":"94","author":"M Abercrombie","year":"1946","unstructured":"Abercrombie, M. Estimation of nuclear population from microtome sections. Anat. Rec. 94, 239\u2013247 (1946).","journal-title":"Anat. Rec."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08700-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08700-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08700-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T03:03:27Z","timestamp":1747883007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08700-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":47,"journal-issue":{"issue":"8064","published-print":{"date-parts":[[2025,5,22]]}},"alternative-id":["8700"],"URL":"https:\/\/doi.org\/10.1038\/s41586-025-08700-0","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.S., R.T. and J.T. received a grant for collaborative research from Sumitomo Pharma. R.T. received a research grant from Nihon Medi-Physics. T.O. received a research grant from Siemens Healthcare. S.H. is an employee of Sumitomo Pharma. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}